Wire · opportunities
Jaypirca breaks into first-line CLL/SLL with FDA approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
The US FDA approved Jaypirca (pirtobrutinib) as a monotherapy for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletion, based on Phase III trial results showing significant progression-free survival benefit compared to bendamustine plus rituximab.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 2 Oct 2026 and 6 Oct 2026.
◆ ◆ The Wire takeaway
Your drug just cleared the first-line bar in a competitive leukemia market. This opens an early treatment door but means you must now compete directly with established BTK inhibitors like zanubrutinib.
◆ Coverage
9 sources · first reported 2 Oct 2026 · latest 6 Oct 2026
◆ Related on Wire
◆ Topics